Rheumnow Podcast

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com  

Dr. Jack Cush reviews the terms in rheumatology that should no longer be used in the field of rheumatology. This lecture is part of the RheumNow Live 2024 meeting, being held January 27-28, 2024 in Dallas, TX (and virtually).

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com

Moderated by Dr. Jack Cush and featuring Drs. Aurelie Najm, David Liew and Jonathan Kay

Featuring Drs. Jack Cush, Yuz Yusof, and Andrea Fava

Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash

Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.  

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter? Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab Does Telemonitoring in SpA Work? Dr. Antoni Chan reports on abstract OP0120 from Eular 2024 in Vienna, Austria. Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria. Treat to Target Outcomes in Early AxSpA Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria. Early Diagnosis of Axial Spondyloarthritis Dr. Antoni Chan reports on abstract OP0310 presented at Eular 2024 in Vienna, Austria. Imaging in Axial Spondyloarthritis Dr. Antoni Chan reviews abstracts OP0222 and OP0303 presented at Eular 2024 in Vienna, Austria.

Does B Cell Depletion Matter? Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria. 3 Big Lupus Themes from EULAR 2024 Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.  POS0732 OP0255 Voclosporin and Steroids in Lupus Nephritis Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Cognitive Function in Older Adults with Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. Does Withdrawing Steroids Increase Flares in SLE? Dr. Janet Pope reports on abstract OP0180 presented at Eular 2024 in Vienna, Austria. Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity at Eular 2024 in Vienna, Austria. We've Got to Talk about CAR T cells Dr. Yuz Yusof discusses abstract OP0017 presented at the Eular 2024 meeting in Vienna, Austria.    

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. Depression and Anxiety Associated with Inability to Achieve Remission in RA and PsA Dr. Aurelie Najm reports on abstract POS0946 presented at Eular 2024 in Vienna, Austria. PsA Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. Axial & Psoriatic Disease Dr. Peter Nash at Eular 2024 in Vienna, Austria. Difficult to Treat Psoriatic Arthritis Dr. Peter Nash reports at Eular 2024 in Vienna, Austria. Predictors of Treatment Response in Psoriatic Arthritis Dr. Janet Pope reviews three abstracts presented at Eular 2024 in Vienna, Austria. Abstracts discussed:  POS 0990 POS 0992 POS 0266 Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.